Breast cancer 2
Cyclooxygenase 2 and selenium in breast cancer
... Breast cancer is a global problem. Worldwide, breast cancer accounts for nearly a quarter of all cancers in women ...with breast cancer ...National Cancer Institute (NCI) ...
7
Review Article Prognostic role of microRNA 125b invarious cancers: a meta-analysis
... included breast cancer (2 studies), gastric cancer (2 studies), hepatocellular carcinoma (2 studies), colorectal cancer (2 studies), non-small cell lung ...
9
Current biomarkers of canine mammary tumors
... human breast cancers (HBC), human biomarkers of HBC are also detectable in cases of ...miRNAs, cancer stem cells, and circulating tumor cells, as well as mutations of the breast cancer 1 gene ...
13
Smoking at time of diagnosis and breast cancer specific survival: new findings and systematic review with meta analysis
... to breast cancer risk [22-25] or to prognosis of breast cancer [2,25-28]: year of diagnosis, age at diagnosis, age at menarche, parity, menopausal status, current hormone replacement ther- apy ...
11
Thymidylate synthase gene (TYMS) polymorphisms in sporadic and hereditary breast cancer
... of breast carcinoma; but as the found results show an association, other studies would be necessary, increasing the number of individuals with lack of imba- lance of constant allele frequencies found, for the same ...
6
Knowledge, attitude, and practice of breast Cancer among nurses in hospitals in Asmara, Eritrea
... of breast cancer has been found to be low [14, 16, 20] whilst other studies have reported nurses’ knowledge about risk factors of breast cancer to be high ...of breast cancer [5] ...
7
R&D Landscape for Breast Cancer through Patent Documents
... for breast cancer and other diseases were from Group 1, principally proteins and antibodies, while a smaller proportion were for oligonucleotides, nucleic acids, recombinant RNA and microRNA (Group ...and ...
9
Genetic risk variants associated with in situ breast cancer
... BC: breast cancer; BCAC: Breast Cancer Association Consortium; BCIS: breast cancer in situ; BMI: body mass index; BPC3: National Cancer Institute ’ s Breast and ...
10
Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers.
... Australian Breast Cancer Family Study; ABCS, Amsterdam Breast Cancer Study; BBCC, Bavarian Breast Cancer Cases and Controls; BBCS, British Breast Cancer Study; ...
25
Aberrant miRNAs expressed in HER-2 negative breast cancers patient
... The miRNA profiling study for plasma samples was conducted on a total of 45 patients. The immunohisto- chemistry (IHC) analysis had previously revealed that 20 cases had TNBC and 14 cases had DPBC. A PCR-array study was ...
16
Breast Cancer- In 21st Century Current Status and Future Perspective
... every 2 weeks (also called dose-dense chemotherapy), once every 3 weeks, or even once every 4 ...for breast cancer include: Cisplatin (Platinol) Cyclophosphamide (Neosar) Docetaxel (Docefrez, ...
6
The Role of miR-526b in COX-2 Mediated Human Breast Cancer Progression and Induction of Stem-Like Phenotype Via EP4 Receptor Signaling
... Previous work in our lab by Majumder et al. (2012) established that stable transfection and over-expression of the COX-2 gene in MCF-7 (ER+, HER2-, COX-2-) and SKBR-3 (ER-, HER2+, COX-2-) human ...
136
Assessing breast cancer cell lines as tumour models by comparison of mRNA expression profiles
... mortalized cancer cell lines [14]. In breast cancer, clus- tering based on expression profiles has elucidated the many clinically relevant subtypes in cell lines and tu- mours (summarized in [15]) ...
12
5181.pdf
... of breast cancer ...of breast cancer survivors in many different ...in breast cancer survivors, especially when compared to healthy age-matched women who have never experienced ...
100
Effectiveness of tocotrienol rich fraction combined with tamoxifen in the management of women with early breast cancer: a pilot clinical trial
... The assessors were also blinded to the treatment received by the trial patients. Baseline assessment included demographic and clinical profiles, such as age, race, breast-cancer stage, and involvement of ...
8
Anti tumor enhancement of Fei Liu Ping ointment in combination with celecoxib via cyclooxygenase 2 mediated lung metastatic inflammatory microenvironment in Lewis lung carcinoma xenograft mouse model
... washed 2 times with the cold PBS, and homogenized 20–40 times in 1 mL mixture of radio-immunoprecipita- tion assay (RIPA) buffer with protease inhibitor (Apply- gen Technologies Inc, Beijing, ...for 2 h at ...
14
Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis
... of breast cancer patients with pan-SFK inhibitors, we next investigated the involvement of individual SFK members (c-Src, Fyn, Yes or Lyn) in the regulation of Claudin-2 ...human breast ...
12
Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
... Network meta-analysis is an approach that allows the simultaneous comparison of multiple treatments that may not have been compared directly in the same study [25–27]. A traditional NMA provides an assessment of all ...
17
Breast Cancer Risk Factors in Iran: A Systematic Review and Meta-analysis
... We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline for study design, search protocol, screening and reporting. A systematic search was performed via international databases ...
49
<p>MORC4 Promotes Chemoresistance of Luminal A/B Breast Cancer via STAT3-Mediated <em>MID2</em> Upregulation</p>
... physical interaction between MORC4 and STAT3 was also con fi rmed. Notably, MORC4 was required for STAT3 binding to the MID2 promoter. These fi ndings collectively suggest a MORC4-STAT3-MID2 regulatory pathway in luminal ...
9